|
|
|
|
|
Nitazoxanide
drug data and news
Nitazoxanide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Nitazoxanide | ||
| Brand Names/Synonyms | Alinia; BRN 1225475; DRG-0242; NITAZOXANIDE; Nitazoxanid; Nitazoxanida [Inn-Spanish]; Nitazoxanide; Nitazoxanide Metabolite; Nitazoxanide [Usan:Inn]; Nitazoxanidum [Inn-Latin]; Tizoxanide Glucuronide | ||
| Indication | For the treatment of diarrhea in adults and children caused by the protozoa Giardia lamblia; For the treatment of diarrhea in children caused by the protozoa Cryptosporidium parvum | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Not Available | ||
| Mechanism Of Action | The antiprotozoal activity of nitazoxanide is believed to be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic energy metabolism. Studies have shown that the PFOR enzyme from Giardia lamblia directly reduces nitazoxanide by transfer of electrons in the absence of ferredoxin. The DNA-derived PFOR protein sequence of Cryptosporidium parvum appears to be similar to that of Giardia lamblia. Interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity. | ||
| Nitazoxanide News (When available) |
Tampa Firm's Medication Has Enormous Potential As Hepatitis ... Feb 24, 2006 Romark to Develop Alinia (nitazoxanide) as New Treatment for ... Jan 10, 2006 Romark Laboratories to Develop Alinia as New Treatment for Chronic ... Jan 10, 2006 (PRN) - CYIOS Corporation Announces Record Quarterly and Annual ... Jan 10, 2006 Romark Advances Development of Alinia in Treating Clostridium ... Dec 8, 2005 Romark Advances Development of Alinia in Treating Clostridium ... Dec 8, 2005 Development of Alinia in Treating Clostridium Difficile-Associated ... Dec 8, 2005 Romark Completes Clinical Study of Alinia in Treating Clostridium ... Nov 18, 2005 AAEP Wrap-Up: Neurologic Disease/WNV Oct 25, 2005 Romark Laboratories to Distribute Alinia to Public Health ... 08 Sep 2005 Romark Labs donates $1 million in drugs for Gulf states 08 Sep 2005 Use of Nitazoxanide As a New Therapeutic Option for Persistent ... Aug 12, 2005 Ind Swift gets DCGI nod for anti-diarrhoeal drug Aug 22, 2005 Romark Laboratories Announces Clinical Study Evaluating Alinia(R) ... Aug 24, 2005 Romark Laboratories Announces Clinical Study Evaluating Alinia for ... Aug 24, 2005 New Drug Study Underway For Chron's Disease Aug 28, 2005 Ind-Swift gets DCGI approval Aug 24, 2005 Romark Laboratories to begin study into Crohn's disease Aug 25, 2005 Ind Swift gets DCGI nod for new drug Aug 23, 2005 EPM Today Aug 22, 2005 Cryptosporidiosis at New York Water Park Sickens a Baker's Dozen Aug 22, 2005 EPM Update Aug 19, 2005 Ind-Swift gets DCGI approval for anti-diarrhoeal drug Jul 22, 2005 Cryptosporidiosis Presenting As Acute Appendicitis: A Case Report Jul 8, 2005 Ind-Swift receives a DCGI approval for its anti-diarrhoeal drug Jul 14, 2005 Cryptosporidiosis Presenting As Acute Appendicitis: A Case Report Jul 8, 2005 FDA Approvals: Revatio, Xeloda, Alinia Jun 23, 2005 Alinia Approved by FDA to Treat Cryptosporidium in Adults Jun 27, 2005 FDA approves treatment for diarrhea caused by Cryptosporidium ... Jun 19, 2005 FDA Approves First-Ever Treatment for Adults, Teens with Diarrhea ... Jun 16, 2005 FDA Approves First-Ever Treatment for Adults, Teens with Diarrhea ... Jun 16, 2005 FDA approves diarrhea drug Jun 17, 2005 | ||
| Dosage Forms | Oral suspension; Tablet | ||
| Drug_Category | Antiparasitics | ||
| Absorption | 70% | ||
| Interactions |
Interactions for Nitazoxanide: Tizoxanide is highly bound to plasma protein (>99.9%). Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin). In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes. Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate | ||
| Chemical Formula | C12H9N3O5S | ||
| Molecular Weight | 307.283 g/mol | ||
| Smiles String | CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-] | ||
| Melting Point | 202 °C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 2.565 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Systemic | ||
| Half Life | Not Available | ||
| Protein Binding [%] | 99% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Nitazoxanide.html http://www.rxlist.com/cgi/generic3/alinia.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00558 | ||
| CAS Registry Number | 55981-09-4 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:182380 | ||
| PharmGKB ID | PA10283 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |